ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has approved Abecma, the first chimeric antigen receptor T-cell (CAR-T) product for the treatment of multiple myeloma. Unlike other CAR-T treatments, which recognize a cancer marker called CD19, Abecma, from Bristol Myers Squibb and Bluebird Bio, recognizes a cancer marker called B-cell maturation antigen on the surface of multiple myeloma cells. It will be a treatment option for people who have not responded to four or more other therapies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X